**Core Concept**
The LUMINATE clinical trial program involves the evaluation of a medication for the treatment of noninfectious uveitis, a form of eye inflammation. The correct medication is a monoclonal antibody that targets a specific protein involved in the inflammatory process.

**Why the Correct Answer is Right**
The medication used in the LUMINATE clinical trial program is **aflibercept**, a vascular endothelial growth factor (VEGF) inhibitor. Aflibercept works by binding to VEGF, a protein that promotes angiogenesis and inflammation in the eye, thereby reducing inflammation and preventing vision loss in patients with noninfectious uveitis. This mechanism of action is similar to other anti-VEGF medications used to treat age-related macular degeneration and diabetic macular edema.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because it is not a medication used for noninfectious uveitis in the LUMINATE clinical trial program.
* **Option B:** This option is incorrect because it is a medication used for a different indication, such as age-related macular degeneration or diabetic retinopathy.
* **Option C:** This option is incorrect because it is not a medication used for noninfectious uveitis in the LUMINATE clinical trial program.

**Clinical Pearl / High-Yield Fact**
Aflibercept is a VEGF inhibitor that has been shown to be effective in reducing inflammation and preventing vision loss in patients with noninfectious uveitis. It is an important medication for ophthalmologists to consider in the treatment of this condition.

**Correct Answer:** C. Aflibercept.